Amyloidosis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Megan Merlo (talk | contribs) No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Amyloidosis}} | {{Amyloidosis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SHH}} | ||
==Overview== | ==Overview== | ||
==Laboratory Findings== | ==Laboratory Findings== | ||
* | * Cardiac biomarkers are the most important predictors of outcome in amyloidosis and provide a quantitative assessment for: | ||
** Cardiac damage (Troponin I or Troponin T) | |||
** Wall strain (BNP and NT-proBNP) | |||
** | |||
** | |||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Medicine]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 14:39, 3 May 2018
Amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Amyloidosis laboratory findings On the Web |
American Roentgen Ray Society Images of Amyloidosis laboratory findings |
Risk calculators and risk factors for Amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
Laboratory Findings
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis and provide a quantitative assessment for:
- Cardiac damage (Troponin I or Troponin T)
- Wall strain (BNP and NT-proBNP)